OVERVIEW OF ACTIVITY
OVERVIEW OF ACTIVITY
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of head and neck cancers and thyroid cancer.
OVERVIEW OF ACTIVITY
OVERVIEW OF ACTIVITY
In 2015 in the United States alone, it is estimated that 220,800 new cases of prostate cancer (PC) will occur. With an estimated 27,540 deaths in 2015, PC is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PC is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.
OVERVIEW OF ACTIVITY
OVERVIEW OF ACTIVITY
In 2015 in the United States alone it is estimated that 220,800 new cases of prostate cancer (PC) will occur. With an estimated 27,540 deaths in 2015, PC is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PC is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.
OVERVIEW OF ACTIVITY
OVERVIEW OF ACTIVITY
OVERVIEW OF ACTIVITY
OVERVIEW OF ACTIVITY
OVERVIEW OF ACTIVITY
Lung cancer is one of the most rapidly evolving fields in oncology nursing and is a major public health concern. In
2015, lung cancer will culminate in 221,200 new cases and an estimated 158,040 deaths in the United States.
Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of
patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a
modest effect on long-term outcomes. However, the advent of novel therapies has led to recent improvements in
disease-free and overall survival in select patient populations. Additionally, published results from ongoing clinical
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows, gastrointestinal surgeons and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.